PL3345900T3 - 2,4-di-(grupa zawierająca azot)-podstawiony związek pirymidynowy i jego sposób otrzymywania oraz zastosowanie - Google Patents

2,4-di-(grupa zawierająca azot)-podstawiony związek pirymidynowy i jego sposób otrzymywania oraz zastosowanie

Info

Publication number
PL3345900T3
PL3345900T3 PL16840692.4T PL16840692T PL3345900T3 PL 3345900 T3 PL3345900 T3 PL 3345900T3 PL 16840692 T PL16840692 T PL 16840692T PL 3345900 T3 PL3345900 T3 PL 3345900T3
Authority
PL
Poland
Prior art keywords
preparation
containing group
nitrogen containing
pyrimidine compound
substituted pyrimidine
Prior art date
Application number
PL16840692.4T
Other languages
English (en)
Inventor
Xiong Cai
Changgeng Qian
Yunwo WENG
Bin Liu
Yanyan Wang
Mingsheng LIN
Junqi Li
Yuanhui QING
Huajin YOU
Shiqing ZHOU
Weicai XUE
Original Assignee
Bebetter Med Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bebetter Med Inc. filed Critical Bebetter Med Inc.
Publication of PL3345900T3 publication Critical patent/PL3345900T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL16840692.4T 2015-08-31 2016-07-26 2,4-di-(grupa zawierająca azot)-podstawiony związek pirymidynowy i jego sposób otrzymywania oraz zastosowanie PL3345900T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510552982 2015-08-31
CN201610471043.7A CN106117185B (zh) 2015-08-31 2016-06-22 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
PCT/CN2016/091755 WO2017036263A1 (zh) 2015-08-31 2016-07-26 2,4-二含氮基团取代嘧啶类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
PL3345900T3 true PL3345900T3 (pl) 2024-10-28

Family

ID=57268890

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16840692.4T PL3345900T3 (pl) 2015-08-31 2016-07-26 2,4-di-(grupa zawierająca azot)-podstawiony związek pirymidynowy i jego sposób otrzymywania oraz zastosowanie

Country Status (11)

Country Link
US (1) US11267802B2 (pl)
EP (1) EP3345900B1 (pl)
CN (1) CN106117185B (pl)
AU (1) AU2016314898B2 (pl)
CA (1) CA2997039C (pl)
DK (1) DK3345900T3 (pl)
ES (1) ES2986889T3 (pl)
HR (1) HRP20241103T1 (pl)
PL (1) PL3345900T3 (pl)
SI (1) SI3345900T1 (pl)
WO (1) WO2017036263A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054987A1 (zh) * 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
TWI739753B (zh) 2015-07-16 2021-09-21 大陸商正大天晴藥業集團股份有限公司 苯胺嘧啶衍生物及其用途
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技(上海)有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Cs醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
CN107266426A (zh) * 2017-08-15 2017-10-20 南通因诺威医药科技有限公司 2‑氨烃基嘧啶类化合物及其制备方法和用途
CN110790749B (zh) * 2018-08-03 2023-07-14 北京普祺医药科技股份有限公司 一种含氮杂环化合物、药物组合物以及其用途
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN112409192A (zh) * 2020-11-26 2021-02-26 启东东岳药业有限公司 一种4-氟-2-甲氧基苯胺的纯化方法
CN115867539B (zh) * 2020-12-02 2025-07-22 上海和誉生物医药科技有限公司 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
AU2022312430A1 (en) * 2021-07-13 2024-02-29 ACEA Therapeutics, Inc. Heterocyclic compounds and uses thereof
CN115701429B (zh) * 2021-08-02 2024-03-12 上海和誉生物医药科技有限公司 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用
CN116514723A (zh) * 2023-03-22 2023-08-01 上海麦克林生化科技股份有限公司 一种5,6-2氯-1-乙基-1h-苯并咪唑-2酮(dcebio)的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
WO2015188777A1 (en) * 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
EP3778584A1 (en) * 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
CN106458969A (zh) * 2014-08-25 2017-02-22 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
WO2016054987A1 (zh) * 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技(上海)有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105525A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
CN105001208A (zh) * 2015-08-06 2015-10-28 南京雷科星生物技术有限公司 一种表皮生长因子受体egfr抑制剂及其制备方法与用途
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技(上海)有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Cs醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑

Also Published As

Publication number Publication date
HK1250706A1 (en) 2019-01-11
CN106117185A (zh) 2016-11-16
CA2997039A1 (en) 2017-03-09
CA2997039C (en) 2020-09-22
WO2017036263A1 (zh) 2017-03-09
ES2986889T3 (es) 2024-11-13
DK3345900T3 (da) 2024-08-19
CN106117185B (zh) 2017-11-07
US20200165227A1 (en) 2020-05-28
AU2016314898B2 (en) 2019-06-27
EP3345900B1 (en) 2024-06-12
HRP20241103T1 (hr) 2024-11-08
US20200331891A9 (en) 2020-10-22
AU2016314898A1 (en) 2018-04-26
EP3345900A1 (en) 2018-07-11
US11267802B2 (en) 2022-03-08
EP3345900A4 (en) 2019-04-10
SI3345900T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
PL3345900T3 (pl) 2,4-di-(grupa zawierająca azot)-podstawiony związek pirymidynowy i jego sposób otrzymywania oraz zastosowanie
SG11202000532SA (en) Compounds, compositions and methods
PT3676297T (pt) Compostos, composições e métodos
PL3421038T3 (pl) Związek naftyrydyny, kompozycja farmaceutyczna i ich zastosowanie
ZA201908488B (en) Substituted nitrogen containing compounds
IL262020B (en) Grisiofulvin compound, preparations containing it and its uses
SG11202007554TA (en) Dioxazoline compound, preparation method therefor, and uses thereof
ZA201805600B (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
IL261782A (en) Carbapenem compounds, preparations containing them and their uses
SG11201809760TA (en) Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
PT3350150T (pt) 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização
HUE047537T2 (hu) Új heterociklusos vegyület, eljárás annak elõállítására, és az azt tartalmazó gyógyászati készítmény
SG11201705533SA (en) Levelling compound, its use and manufacture
PL3263133T3 (pl) Związek pirydynonu i jego zastosowanie
IL256252B (en) Imidazodiazepine compound, preparations containing it and its uses
IL255042B (en) Amphiphilic compounds, their preparations and uses
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
SG11202001569SA (en) Marker compositions with nitrogen compounds, and methods for making and using same
EP3293179A4 (en) Amide compound and the preparation method and use thereof
ZA201708307B (en) Improved herbicidal composition, method and use
GB2542135B (en) A fungicidal composition, method and use of the same
GB201518402D0 (en) Products, uses & methods (8)
GB201510891D0 (en) Products, uses & methods (7)
GB201509366D0 (en) Products, uses & methods (6)
GB201507773D0 (en) Products, uses & methods (1)